CN101742910A - 治疗脑癌的方法 - Google Patents

治疗脑癌的方法 Download PDF

Info

Publication number
CN101742910A
CN101742910A CN200880019674A CN200880019674A CN101742910A CN 101742910 A CN101742910 A CN 101742910A CN 200880019674 A CN200880019674 A CN 200880019674A CN 200880019674 A CN200880019674 A CN 200880019674A CN 101742910 A CN101742910 A CN 101742910A
Authority
CN
China
Prior art keywords
methyl
phenyl
methoxy
quinazolin
effective dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880019674A
Other languages
English (en)
Chinese (zh)
Inventor
马克·劳克林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myrexis Inc
Original Assignee
Myriad Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myriad Pharmaceuticals Inc filed Critical Myriad Pharmaceuticals Inc
Publication of CN101742910A publication Critical patent/CN101742910A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN200880019674A 2007-04-10 2008-04-10 治疗脑癌的方法 Pending CN101742910A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91097507P 2007-04-10 2007-04-10
US60/910,975 2007-04-10
PCT/US2008/059905 WO2008124822A1 (en) 2007-04-10 2008-04-10 Method of treating brain cancer

Publications (1)

Publication Number Publication Date
CN101742910A true CN101742910A (zh) 2010-06-16

Family

ID=39831435

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880019674A Pending CN101742910A (zh) 2007-04-10 2008-04-10 治疗脑癌的方法

Country Status (9)

Country Link
US (1) US20100129470A1 (enExample)
EP (1) EP2144504A4 (enExample)
JP (1) JP2010523696A (enExample)
KR (1) KR20100016385A (enExample)
CN (1) CN101742910A (enExample)
AU (1) AU2008236993A1 (enExample)
CA (1) CA2720982A1 (enExample)
NZ (1) NZ580866A (enExample)
WO (1) WO2008124822A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105288629A (zh) * 2014-05-28 2016-02-03 北京大学 具有药效叠加作用及毒性分散效应的组合药物之设计方案
CN111825610A (zh) * 2020-06-24 2020-10-27 中国药科大学 一种具有抗肿瘤活性的2-甲基喹啉类衍生物及其合成方法和用途
CN113842392A (zh) * 2013-06-05 2021-12-28 西特克斯公司 用于治疗癌症的细胞毒素剂

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5235662B2 (ja) * 2005-06-16 2013-07-10 ミリアド ジェネティクス， インコーポレイテッド 薬学的組成物およびその使用
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
EP2144886A4 (en) * 2007-04-10 2012-10-03 Myrexis Inc METHOD OF TREATING MELANOMA
AU2008236997A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Methods for treating cancer
WO2008124824A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Dosages and methods for the treatment of cancer
EP2309856A4 (en) * 2008-07-11 2012-03-28 Myrexis Inc PHARMACEUTICAL COMPOUNDS AS CYTOTOXICA AND ITS APPLICATION
US20110224240A1 (en) * 2010-01-11 2011-09-15 Myrexis, Inc. Methods of treating cancer and related diseases
KR101343959B1 (ko) 2012-09-19 2013-12-24 한국기계연구원 통합 코팅 장치
WO2016168637A2 (en) 2015-04-17 2016-10-20 Duquesne University Of The Holy Spirit Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibition and antitumor agents
US11497793B2 (en) * 2018-05-02 2022-11-15 Tel Hashomer Medical Research Infrastructure And Services Ltd. Compositions and methods for treating glioblastoma
US12220604B2 (en) * 2018-07-31 2025-02-11 Daiichi Sankyo Company, Limited Treatment of metastatic brain tumor by administration of an antibody-drug conjugate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050137213A1 (en) * 2003-07-03 2005-06-23 Myriad Genetics, Incorporated Compounds and therapeutical use thereof
WO2006074187A2 (en) * 2005-01-03 2006-07-13 Myriad Genetics, Inc. Method of treating brain cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4317399A (en) * 1998-05-28 1999-12-13 Parker Hughes Institute Quinazolines for treating brain tumor
US7001926B2 (en) * 2000-03-10 2006-02-21 Oxigene, Inc. Tubulin binding agents and corresponding prodrug constructs
US20040229960A1 (en) * 2001-07-13 2004-11-18 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
PL369336A1 (en) * 2001-09-21 2005-04-18 The Administrators Of The Tulane Educational Fund Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
US7470723B2 (en) * 2003-03-05 2008-12-30 Celgene Corporation Diphenylethylene compounds and uses thereof
SG135193A1 (en) * 2003-08-18 2007-09-28 Pfizer Prod Inc Dosing schedule for erbb2 anticancer agents
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
US8258145B2 (en) * 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
HUE038768T2 (hu) * 2005-02-18 2018-11-28 Abraxis Bioscience Llc Terápiás szerek kombinációi, valamint beadásukra szolgáló módszerek, és kombinációs terápia
US20070249640A1 (en) * 2005-06-16 2007-10-25 Myriad Genetics, Incorporated Pharmaceutical compositions and use thereof
JP5235662B2 (ja) * 2005-06-16 2013-07-10 ミリアド ジェネティクス， インコーポレイテッド 薬学的組成物およびその使用
US20070065449A1 (en) * 2005-09-16 2007-03-22 Claire Verschraegen Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
WO2008124824A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Dosages and methods for the treatment of cancer
AU2008236997A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Methods for treating cancer
EP2144886A4 (en) * 2007-04-10 2012-10-03 Myrexis Inc METHOD OF TREATING MELANOMA
WO2009023876A1 (en) * 2007-08-16 2009-02-19 Myriad Genetics, Inc. Method of treating non-small cell lung cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050137213A1 (en) * 2003-07-03 2005-06-23 Myriad Genetics, Incorporated Compounds and therapeutical use thereof
WO2006074187A2 (en) * 2005-01-03 2006-07-13 Myriad Genetics, Inc. Method of treating brain cancer

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113842392A (zh) * 2013-06-05 2021-12-28 西特克斯公司 用于治疗癌症的细胞毒素剂
CN105288629A (zh) * 2014-05-28 2016-02-03 北京大学 具有药效叠加作用及毒性分散效应的组合药物之设计方案
CN105288629B (zh) * 2014-05-28 2021-02-19 北京大学 具有药效叠加作用及毒性分散效应的组合药物
CN111825610A (zh) * 2020-06-24 2020-10-27 中国药科大学 一种具有抗肿瘤活性的2-甲基喹啉类衍生物及其合成方法和用途
CN111825610B (zh) * 2020-06-24 2023-03-31 中国药科大学 一种具有抗肿瘤活性的2-甲基喹啉类衍生物及其合成方法和用途

Also Published As

Publication number Publication date
US20100129470A1 (en) 2010-05-27
EP2144504A1 (en) 2010-01-20
JP2010523696A (ja) 2010-07-15
NZ580866A (en) 2011-02-25
EP2144504A4 (en) 2012-10-03
CA2720982A1 (en) 2008-10-16
WO2008124822A1 (en) 2008-10-16
AU2008236993A1 (en) 2008-10-16
KR20100016385A (ko) 2010-02-12

Similar Documents

Publication Publication Date Title
CN101742910A (zh) 治疗脑癌的方法
EP3148529B1 (en) Compounds for treating brain cancer
ES2774930T3 (es) Activación de procaspasa 3 mediante terapia de combinación
JP7611855B2 (ja) ユーイング肉腫治療用キノリン系化合物又はその薬学的に許容される塩
EP3443962B1 (en) Quinoline derivative for treating gastric cancer
US11311552B2 (en) Therapies for cancer
US20100087458A1 (en) Method of treating melanoma
US20100261739A1 (en) Method of Treating Non-Small Cell Lung Cancer
CN101687104A (zh) 包括长春氟宁和曲妥单抗的癌症治疗联合疗法
CN1658880A (zh) 用于治疗癌症的联合疗法
TW202114694A (zh) 四環化合物及其鹽類、組合物、及彼等之使用方法
KR102005887B1 (ko) 뇌종양의 예방 또는 치료용 약학 조성물
CN111643502A (zh) 喹啉衍生物联合化疗药物用于治疗非小细胞肺癌
CN104968340A (zh) 治疗肝脏疾病或病状的用途和方法
JP2010526073A (ja) 癌または前癌性症状およびその他の症状の治療のためのジヒドロピリジン誘導体
WO2025083568A1 (en) Novel small-molecule protein kinase inhibitors for implications in cancer treatment
WO2025032079A1 (en) Combination of a mps1 inhibitor and an antibody drug conjugate
CN118338900A (zh) 含尼罗加司他的组合物和治疗
US9872882B2 (en) Aurantiamide dipeptide derivatives for treatment or prevention of angiogenesis-related diseases
WO2019223672A1 (zh) 用于治疗非小细胞肺癌的喹啉衍生物
HK1245120B (en) Novel therapies for cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100616